References
1. Wang T, Hou Y, Wang R. A case report of community-acquired
Pseudomonas aeruginosa pneumonia complicated with MODS in a previously
healthy patient and related literature review. BMC Infect Dis.2019;19(1):130.
2. Huang YC, Lin TY, Wang CH. Community-acquired Pseudomonas aeruginosa
sepsis in previously healthy infants and children: analysis of
forty-three episodes. Pediatr Infect Dis J.2002;21(11):1049-1052.
3. Zhang Q, Smith JC, Zhu Q, Guo Z, MacDonald NE. A five-year review of
Pseudomonas aeruginosa bacteremia in children hospitalized at a single
center in southern China. Int J Infect Dis. 2012;16(8):e628-632.
4. Asumang A, Goldsmith AL, Dryden M. Subcutaneous nodules with
pseudomonas septicaemia in an immunocompetent patient. Anaesth
Intensive Care. 1999;27(2):213-215.
5. Asgari S, McLaren PJ, Peake J, et al. Exome Sequencing Reveals
Primary Immunodeficiencies in Children with Community-Acquired
Pseudomonas aeruginosa Sepsis. Front Immunol. 2016;7:357.
6. Kunimasa K, Ishida T, Kimura S, et al. Successful treatment of
fulminant community-acquired Pseudomonas aeruginosa necrotizing
pneumonia in a previously healthy young man. Intern Med.2012;51(17):2473-2478.
7. Xu Y, Jin D, Ye H, Liang Y. A rare case of Pseudomonas aeruginosa
bacteremia in a newborn with 58 perforations in the small intestine.BMC Pediatr. 2021;21(1):9.
8. Wang J, Yun L, Zhao H, Li X. Combination Therapy of Polymyxin B and
Amikacin for Community-Acquired Pseudomonas aeruginosa Pneumonia with
MODS in a Previously Healthy Patient: A Case Report. Infect Drug
Resist. 2021;14:2895-2900.
9. Cilloniz C, Gabarrus A, Ferrer M, et al. Community-Acquired Pneumonia
Due to Multidrug- and Non-Multidrug-Resistant Pseudomonas aeruginosa.Chest. 2016;150(2):415-425.
10. Khawaja A, Zubairi AB, Durrani FK, Zafar A. Etiology and outcome of
severe community acquired pneumonia in immunocompetent adults. BMC
Infect Dis. 2013;13:94.
11. Takajo D, Iwaya K, Katsurada Y, et al. Community-acquired lobar
pneumonia caused by Pseudomonas aeruginosa infection in Japan: a case
report with histological and immunohistochemical examination.Pathol Int. 2014;64(5):224-230.
12. Cilloniz C, Dominedo C, Nicolini A, Torres A. PES Pathogens in
Severe Community-Acquired Pneumonia. Microorganisms. 2019;7(2).
13. Hattemer A, Hauser A, Diaz M, et al. Bacterial and clinical
characteristics of health care- and community-acquired bloodstream
infections due to Pseudomonas aeruginosa. Antimicrob Agents
Chemother. 2013;57(8):3969-3975.
14. Paraskaki I, Lebessi E, Legakis NJ. Epidemiology of
community-acquired Pseudomonas aeruginosa infections in children.Eur J Clin Microbiol Infect Dis. 1996;15(10):782-786.
15. Kim HS, Park BK, Kim SK, et al. Clinical characteristics and
outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic
children and adolescents with the impact of antibiotic resistance: a
retrospective study. BMC Infect Dis. 2017;17(1):500.
16. Cardozo C, Rico V, Agüero D, Soriano A. Antibiotic selection in the
treatment of acute invasive infections by Pseudomonas aeruginosa.Revista espanola de quimioterapia : publicacion oficial de la
Sociedad Espanola de Quimioterapia. 2019;32 Suppl 2(Suppl 2):32-34.
17. Henderson A, Kelly W, Wright M. Fulminant primary Pseudomonas
aeruginosa pneumonia and septicaemia in previously well adults.Intensive Care Med. 1992;18(7):430-432.
18. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign
guidelines for management of severe sepsis and septic shock.Intensive Care Med. 2004;30(4):536-555.
19. Zhao GJ, Hong GL, Liu JQ, Lu Y, Lu ZQ. Septic shock due to
community-acquired Pseudomonas aeruginosa necrotizing fasciitis: A case
report and literature review. Exp Ther Med. 2014;7(6):1545-1548.
20. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases
Society of America/American Thoracic Society consensus guidelines on the
management of community-acquired pneumonia in adults. Clin Infect
Dis. 2007;44 Suppl 2(Suppl 2):S27-72.
21. Wu J, Zhong W, Yin Y, Zhang H. Primary immunodeficiency disease: a
retrospective study of 112 Chinese children in a single tertiary care
center. BMC Pediatr. 2019;19(1):410.
22. Tsai HY, Yu HH, Chien YH, et al. X-linked hyper-IgM syndrome with
CD40LG mutation: two case reports and literature review in Taiwanese
patients. J Microbiol Immunol Infect. 2015;48(1):113-118.
23. Lin SC, Shyur SD, Lee WI, Ma YC, Huang LH. X-linked
hyper-immunoglobulin M syndrome: molecular genetic study and long-time
follow-up of three generations of a Chinese family. Int Arch
Allergy Immunol. 2006;140(1):1-8.
24. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of
X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):47-54.
25. Schneider LC. X-linked hyper IgM syndrome. Clin Rev Allergy
Immunol. 2000;19(2):205-215.
26. Montella S, Maglione M, Giardino G, et al. Hyper IgM syndrome
presenting as chronic suppurative lung disease. Italian journal of
pediatrics. 2012;38:45.
27. de la Morena MT. Clinical Phenotypes of Hyper-IgM Syndromes. J
Allergy Clin Immunol Pract. 2016;4(6):1023-1036.